1092477-86-5

Basic information

• Product Name: Methyl 2-(3-chloropyridin-2-yl)acetate
• Synonyms: Methyl 2-(3-chloropyridin-2-yl)acetate
• CAS NO: 1092477-86-5
• Molecular Formula: C8H8ClNO2
• Molecular Weight: 185.60762
• Mol File: 1092477-86-5.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Methyl 2-(3-chloropyridin-2-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-(3-chloropyridin-2-yl)acetate(1092477-86-5)
• EPA Substance Registry System: Methyl 2-(3-chloropyridin-2-yl)acetate(1092477-86-5)

Safety Data

• Hazardous Substances Data: 1092477-86-5(Hazardous Substances Data)

Upstream product

• 1092477-85-4 (3-chloro-2-pyridinyl)acetic acid hydrochloride 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 2402-77-9 2,3-dichloro-pyridine 
• 185315-52-0 (3-chloro-2-pyridinyl)-acetonitrile 
• 67-56-1 methanol 
• 885167-73-7 2-(3-chloropyridin-2-yl)acetic acid 

Downstream Products

• 1092477-90-1 (+/-)-N'-[3,5-bis(trifluoromethyl)phenyl]-2-(3-chloro-2-pyridinyl)-2-(4-methyl-1-piperazinyl)acetohydrazide 
• 1092476-62-4 (R)-N'-[3,5-bis(trifluoromethyl)phenyl]-2-(3-chloro-2-pyridinyl)-2-(4-methyl-1-piperazinyl)acetohydrazide 
• 1092476-61-3 (S)-N'-[3,5-bis(trifluoromethyl)phenyl]-2-(3-chloro-2-pyridinyl)-2-(4-methyl-1-piperazinyl)acetohydrazide 

Relevant articles and documents

UREA DERIVATIVES AND USES THEREOF

The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.